Core Viewpoint - OptimizeRx Corp. is set to discuss its full year fiscal 2024 financial results and fourth quarter results on March 12, 2025, indicating a focus on transparency and engagement with investors [1]. Group 1: Conference Call Details - The conference call will take place on March 12, 2025, at 8:30 a.m. Eastern Time [2]. - Participants can join via a toll-free number or an international line, with specific access details provided [2]. - A replay of the call will be available for 12 months on the company's investor relations website [3]. Group 2: Company Overview - OptimizeRx provides innovative technology that enhances engagement between life sciences organizations, healthcare providers, and patients [4]. - The company has the capability to synchronize messaging across 2 million healthcare providers and over 240 million adults through various digital channels [4].

Company Leadership Transition - William J. Febbo, CEO of OptimizeRx, will depart the company effective December 31, 2024, to pursue other opportunities, while providing advisory services until March 31, 2025 [9] - Stephen Silvestro has been appointed as the interim CEO during the search for a new candidate, having previously served as Chief Commercial Officer and President [10] Company Growth and Strategy - OptimizeRx has experienced significant growth under Febbo's leadership, transforming from a single point of care product to an omnichannel platform, and is well-positioned for future growth [1] - The company reaffirms its financial guidance for the full year 2024, expecting to achieve results at the higher end of its revenue and adjusted EBITDA guidance range [2] Company Overview - OptimizeRx provides healthcare technology solutions that facilitate engagement between life sciences organizations, healthcare providers, and patients, connecting over 2 million U.S. healthcare providers through its digital point-of-care network [6]

Group 1: Earnings Performance - OptimizeRx Corp. reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and up from $0.09 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $21.31 million for the quarter ended September 2024, which missed the Zacks Consensus Estimate by 14.55%, compared to year-ago revenues of $16.33 million [2] - Over the last four quarters, OptimizeRx has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Group 2: Stock Performance and Outlook - OptimizeRx shares have declined approximately 59.2% since the beginning of the year, contrasting with the S&P 500's gain of 25.5% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is $0.39 on revenues of $37.55 million, and for the current fiscal year, it is $0.36 on revenues of $93.34 million [7] Group 3: Industry Context - The Computer - Software industry, to which OptimizeRx belongs, is currently ranked in the top 19% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact OptimizeRx's stock performance [5]

Financial Performance - Q3 2024 revenue increased by 30% year-over-year to $21.3 million, compared to $16.3 million in Q3 2023[2] - Q3 2024 gross profit rose by 37% year-over-year to $13.4 million, with a gross margin of 63%[1] - Non-GAAP net income for Q3 2024 was $2.3 million, or $0.12 per diluted share, up from $1.6 million or $0.09 per diluted share in Q3 2023[3] - Adjusted EBITDA for Q3 2024 was $2.7 million, compared to $0.9 million in the same period last year[3] - GAAP net loss for Q3 2024 was $(9.1) million, or $(0.50) per share, compared to $(2.9) million or $(0.17) per share in Q3 2023[4] - Net revenue for the three months ended September 30, 2024, was $21,309 thousand, a 30.5% increase from $16,331 thousand for the same period in 2023[24] - Gross profit for the nine months ended September 30, 2024, was $37,355 thousand, up 48.8% from $25,059 thousand in the prior year[24] - The net loss for the three months ended September 30, 2024, was $(9,124) thousand, compared to $(2,865) thousand for the same period in 2023, indicating a significant increase in losses[24] Cash and Investments - Cash, cash equivalents, and short-term investments totaled $16.1 million as of September 30, 2024, up from $13.9 million at the end of 2023[4] - Cash provided by operating activities was $4,691 thousand for the nine months ended September 30, 2024, compared to $(982) thousand in the same period of 2023[25] - Cash and cash equivalents at the end of the period were $16,126 thousand, up from $9,923 thousand at the end of September 2023[25] Debt and Equity - The company has paid down an additional $2.0 million of principal on its term loan since the end of Q3 2024[5] - Total stockholders' equity decreased to $114,465 thousand as of September 30, 2024, down from $126,553 thousand at the end of 2023[22] - The company incurred interest expense of $(1,524) thousand for the three months ended September 30, 2024, with total other income (expense) netting to $(1,379) thousand[24] Revenue Expectations and Retention - The company expects full-year 2024 revenue to be between $88 million and $92 million, with Adjusted EBITDA between $8 million and $10 million[7] - The company achieved a net revenue retention rate of 93% for the top 20 pharmaceutical manufacturers[6] - The average revenue per top 20 pharmaceutical manufacturer decreased to $1.902 million from $2.824 million year-over-year[6] Operating Expenses and Impairments - Operating expenses increased to $54,695 thousand for the nine months ended September 30, 2024, compared to $40,557 thousand in the same period of 2023, representing a 35% rise[24] - The company reported a goodwill impairment of $7,489 thousand for the three months ended September 30, 2024[24] Share Information - The weighted average number of shares outstanding for basic loss per share was 18,323,542 for the three months ended September 30, 2024, compared to 16,637,606 for the same period in 2023[24]

Company Overview - OptimizeRx Corp. (OPRX) shares increased by 19.8% to close at $6.12, following a notable trading volume, contrasting with a 27.4% loss over the past four weeks [1] - The company is experiencing strong growth through its Dynamic Audience Activation Platform, which provides predictive and secure marketing across a network connecting patients, healthcare providers, and the life sciences sector [1] Earnings Expectations - The upcoming quarterly earnings report is expected to show earnings of $0.06 per share, reflecting a year-over-year decrease of 33.3%, while revenues are projected to be $24.94 million, an increase of 52.7% from the previous year [2] - The consensus EPS estimate for OptimizeRx has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Industry Context - OptimizeRx is categorized within the Zacks Computer - Software industry, where Intuit (INTU) also operates, having closed 4.8% higher at $648.39, with a 0.9% return over the past month [3] - Intuit's consensus EPS estimate has seen a slight increase of 0.1% to $2.36, representing a year-over-year change of -4.5%, and currently holds a Zacks Rank of 4 (Sell) [4]

WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management wil ...

OptimizeRx Corp. (OPRX) shares soared 5.4% in the last trading session to close at $7.59. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks. The increase in share price can be attributed to higher demand for the company's innovative DAAP (Dynamic Audience Activation Platform) solution. The platform offers predictive and secure marketing solutions, which connect patients, HCPs and life sciences acr ...

WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand program bringing the total in year commitment to over $10 million, which includes the previously mentioned $6 million DAAP contract. This initia ...

The availability of Micro-Neighborhood® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing OptimizeRx presents panel session at Digital Pharma East: Unlocking Opportunity through HCP+DTC Alignment in Omnichannel Oncology Marketing WALTHAM, Ma., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences ...

OptimizeRx Corp. (OPRX) has been beaten down lately with too much selling pressure. While the stock has lost 12.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillato ...